The benefits and risks of alemtuzumab in multiple sclerosis

被引：0
作者：
Ontaneda, Daniel [1 ]
Cohen, Jeffrey A. [1 ]
机构：
[1] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Neurol Inst, Cleveland, OH 44106 USA
来源：
EXPERT REVIEW OF CLINICAL IMMUNOLOGY | 2013年 / 9卷 / 03期
关键词：
alemtuzumab; efficacy; multiple sclerosis; risk; THERAPEUTIC LYMPHOCYTE DEPLETION; DISEASE;
D O I：
10.1586/ECI.13.1
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：189 / 191
页数：3
相关论文
共 50 条
  • [31] Efficacy and safety of alemtuzumab treatment in a real-world cohort of patients with multiple sclerosis
    Zmira, Ofir
    Halpern, Alex, I
    Abraham, Lital
    Achiron, Anat
    ACTA NEUROLOGICA BELGICA, 2021, 121 (06) : 1513 - 1518
  • [32] Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis
    Sainz-Amo, Raquel
    Romero, Alexander Rodero
    Monreal, Enric
    Garcia, Juan Luis Chico
    Velasco, Jose Ignacio Fernandez
    Villarrubia, Noelia
    Gonzalez, Jose Luis Veiga
    de la Maza, Susana Sainz
    Jorge, Fernando Rodriguez
    Masjuan, Jaime
    Costa-Frossard, Lucienne
    Villar, Luisa Maria
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [33] Intractable and highly active relapsing multiple sclerosis - role of alemtuzumab
    Dubey, Divyanshu
    Cano, Christopher A.
    Stuve, Olaf
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2015, 11 : 2405 - 2414
  • [34] Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients
    Rauma, Ilkka
    Mustonen, Tiina
    Seppa, Juha Matti
    Ukkonen, Maritta
    Mannikko, Marianne
    Verkkoniemi-Ahola, Auli
    Kartau, Marge
    Saarinen, Jukka T.
    Luostarinen, Liisa
    Simula, Sakari
    Ryytty, Mervi
    Ahmasalo, Riitta
    Sipila, Jussi O. T.
    Pieninkeroinen, Ilkka
    Tapiola, Tero
    Remes, Anne M.
    Kuusisto, Hanna
    JOURNAL OF NEUROLOGY, 2022, 269 (02) : 824 - 835
  • [35] The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis
    Rolla, Simona
    Maglione, Alessandro
    De Mercanti, Stefania Federica
    Clerico, Marinella
    CELLS, 2020, 9 (06) : 1 - 17
  • [36] Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis
    Babij, Rachel
    Perumal, Jai S.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2015, 11 : 1221 - 1229
  • [37] Sarcoidosis following alemtuzumab treatment for multiple sclerosis
    Willis, Mark D.
    Hope-Gill, Ben
    Flood-Page, Patrick
    Joseph, Fady
    Needham, Ed
    Jones, Joanne
    Coles, Alasdair
    Robertson, Neil P.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (13) : 1779 - 1782
  • [38] Alemtuzumab: a further option for treatment of multiple sclerosis
    Menge, T.
    Kieseier, B. C.
    Warnke, C.
    Aktas, O.
    Hartung, H. -P.
    NERVENARZT, 2012, 83 (04): : 487 - 501
  • [39] Melanoma following treatment with alemtuzumab for multiple sclerosis
    Pace, A. A.
    Zajicek, J. P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 (04) : E70 - E71
  • [40] Alemtuzumab is a new drug based on monoclonal antibodies for treatment multiple sclerosis: treatment possibilities and risks (review)
    Khasayeva, M. A.
    Gorokhova, T. V.
    Boyko, A. N.
    Gusev, E. I.
    ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2013, 113 (02) : 87 - +
12345